Memantine (ebixa) (DrugBank: Memantine)
7 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 1 |
6 | Parkinson disease | 0 |
8 | Huntington disease | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
49 | Systemic lupus erythematosus | 0 |
127 | Frontotemporal lobar degeneration | 0 |
205 | Fragile X syndrome related disease | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00353665 (ClinicalTrials.gov) | July 2005 | 18/7/2006 | Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) | Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Memantine (Ebixa);Drug: riluzole;Drug: Placebo | University of Lisbon | H. Lundbeck A/S | Completed | 20 Years | 75 Years | Both | 63 | Phase 2;Phase 3 | Portugal |